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13202008 Research PrioritiesBased on recent clinical data and advances in un-
derstanding of the biology of hematopoietic stem cell
transplantation (HSCT), the American Society for
Blood and Marrow Transplantation (ASBMT) has
identified research priorities in several areas of basic
and clinical research:
 Advances in stem cell biology (inducible pluripotent
stem cells and cancer stem cells)
 New cellular and molecular therapies for relapse in
autologous and allogeneic HSCT (T cell transfer,
combination with molecular targeting agents, che-
moimmunotherapy)
 Emerging predominance of certain complications,
especially chronic graft-versus-host disease (GVHD)
 Emerging technologies with prognostic and diag-
nostic uses (imaging, proteomics, genomics)
 Wider applications of HSCT for various disease
states (solid organ transplantation, autoimmunity,
potential regenerative applications, radioprotection
in bioterrorism)
 Survivorship issues
All are important areas of interface between clini-
cal experience and basic science. As described below,
research in each of these areas can have direct and
immediate clinical benefits.
STEM CELL BIOLOGY
The demonstration of inducible hematopoietic
stem cells (HSCs) from progenitor cells has opened
the door for stem cell approaches in various diseases.
Understanding of the potential plasticity of HSCs has
obvious implications but requires further research. We
need a better understanding of the biology of stem cells
and their sources (marrow, cord blood, and peripheral
blood). More data on stem cell applications in disease,
aswell as the conditions allowing for optimal reconstitu-
tion and recovery, is another priority. Cancer stem cells,
particularly the leukemia stem cell, may be critically im-
portant. Efforts toward achieving cancer ‘‘cures’’ must
consider and target this cell population. Further preclin-
ical and clinical studies of both inducible pluripotent
stem cells and cancer stem cells are needed.
IMMUNE EFFECTOR POPULATIONS AND
IMMUNOBIOLOGYOF ALLOGENEIC HSCT
Relapse from the cancer and occurrence of
GVHD remain at the forefront of issues in allogeneicHSCT. Adoptive immunotherapy has been shown to
play a role in attacking hematologic malignancies.
Recent reports have described the successful use of
adoptive T cell transfer after reduced-intensity condi-
tioning in melanoma. In addition, T cells have been
shown to play a central role not only in graft-versus-
tumor (GVT) effects, but also in GVHD. Thus,
more work is needed to understand the biology and
application of immunomodulating agents or cellular
therapies. Priorities include research on the traffick-
ing of immune effector cells in GVHD and cancer, re-
constitution of the T cell compartment after HSCT,
cellular regulation of immune cell function and sur-
vival, and the development of preclinical models that
better reflect the clinical scenario (eg, the aging
patient).
Natural killer (NK) cells represent another effector
arm that needs to be better characterized, not only as
an antitumor effector, but also as immunodulatory
cells that can affect outcome. Studies characterizing
the immunomodulatory properties and cellular inter-
actions of potentially useful cell products (regulatory
T cells, NK/T cells, suppressive dendritic cell subsets,
NK cells) in the context of HSCT are a priority. Fi-
nally, molecular targeting agents have the potential
not only to exert immunomodulating effects, but also
to augment the antitumor effects of allogeneic
HSCT. Understanding pathways that can distinguish
GVHD and GVT and the roles of the various immune
cell populations continues to be of paramount impor-
tance for applying HSCT in cancer therapies.
CHRONIC GVHD
There is an urgent need to improve our under-
standing of the biology of chronic GVHD and to de-
velop new ways of targeting it clinically. In addition
to better preclinical models of chronic GVHD and
better prognostic indicators, more efficacious treat-
ments than continuous global immunosuppression
are a top priority. The molecular targeting agents cur-
rently under assessment in acute GVHD also should
be applied to preclinical and subsequent clinical
chronic GVHD. Studies should assess the effects of
age on chronic GVHD, as well as effects of the condi-
tioning used in HSCT on the aged population. These
studies should focus on immunologic recovery and
chronic GVHD risk.
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MONITORING TOOLS
The advent of proteomics and genomics has in-
creased the need to validate potential clinical markers
in GVHD. Such markers have important implications
for patient selection, prognosis, and treatment. Imaging
techniques are needed not only to assess clinical efficacy
and cellular therapy trafficking, but also to advance our
basic understanding of disease processes. Using proteo-
mics to determine correlative markers for GVHD
progression and to identify high-risk patients is of
considerable importance. Another critical area is the
development of immune monitoring parameters that
reflect immune competence and recovery, particularly
with the increasing use of HSCT in older patients.
EXPANDING THE USE OF HSCT
Recent breakthrough studies indicate that HSCT
may have applications in solid organ transplantation
by the induction of immune tolerance. Expanded use
of HSCT may be advantageous in other situations,
including, but not limited to, regenerative medicine
(heart disease and others), autoimmunity, and radiopro-
tection in the advent ofbioterrorismor amass radiologic
accident. For radioprotection/bioterrorism applica-
tions, we need to develop ways of applying HSCT to
large populations, along with means of augmenting
recovery. Preclinical and clinical studies of immune
reconstitution, tolerance (including appropriate func-
tional correlates), efficacy, and long-term effects will
aid in understanding the applicability ofHSCT in these
conditions. Means of expanding the application of
HSCT in solid cancers are an ongoing priority. We
also need to define the optimal stem cell source
(e.g. cord blood, ex vivo expanded stem cell populations,
peripheral stem cells), banking, and typing, particularly
as they relate to the treatment of specific diseases.
PREVENTION OF TUMOR RELAPSE
Relapse remains of paramount concern after autol-
ogous HSCT to treat hematologic malignancies. We
need to understand the mechanisms by which cancercells can resist cytotoxic therapies in autologous
HSCT. Use of immune therapies, monoclonal
antibodies, molecular targeted agents, and chemother-
apeutics—alone and in combination—should be ex-
plored in the context of HSCT. This may also help
in applying autologous HSCT to a wider spectrum
of malignancies.
SURVIVORSHIP
HSCT is being used in a more elderly population.
As more patients survive the initial period after trans-
plantation, many are living free of recurrent malig-
nancy. Currently, however, a substantial proportion
of these patients develop late complications, including
chronic GVHD, immune deficiency, endocrinologic
failure, bone loss, and secondary malignancies. These
events can adversely affect the quality of life for long-
term transplantation survivors. Of high priority are
investigating risk factors for late complications, devel-
oping more relevant preclinical models, designing
interventional strategies, and developing better means
of assessing quality of life in long-term survivors. In
addition, the long period of immune deficiency that
follows HSCT leaves this population at risk for oppor-
tunistic infections; therefore, development of means to
promote immune reconstitution is a priority, particu-
larly in the elderly.
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